Explore
Validate
Learn60233-1-Ig
antibody from Proteintech Group
Targeting: MYH9
DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 60233-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- MYH9 antibody
- Antibody type
- Monoclonal
- Description
- KD/KO validated MYH9 antibody (Cat. #60233-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, mouse, pig and has been validated for the following applications: IF, WB,ELISA.
- Reactivity
- Human, Mouse, Porcine
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 5D9D2
- Vial size
- 20ul, 150ul
Submitted references Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-β-catenin-STAT3 signaling.
Salvia miltiorrhiza-derived miRNAs suppress vascular remodeling through regulating OTUD7B/KLF4/NMHC IIA axis.
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Lymphocyte-specific protein 1 regulates mechanosensory oscillation of podosomes and actin isoform-based actomyosin symmetry breaking.
Hu S, Ren S, Cai Y, Liu J, Han Y, Zhao Y, Yang J, Zhou X, Wang X
Cell death and differentiation 2022 Mar;29(3):642-656
Cell death and differentiation 2022 Mar;29(3):642-656
Salvia miltiorrhiza-derived miRNAs suppress vascular remodeling through regulating OTUD7B/KLF4/NMHC IIA axis.
Yang GS, Zheng B, Qin Y, Zhou J, Yang Z, Zhang XH, Zhao HY, Yang HJ, Wen JK
Theranostics 2020;10(17):7787-7811
Theranostics 2020;10(17):7787-7811
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.
Zhang D, Kinloch AJ, Srinath A, Shenkar R, Girard R, Lightle R, Moore T, Koskimäki J, Mohsin A, Carrión-Penagos J, Romanos S, Shen L, Clark MR, Shi C, Awad IA
Journal of autoimmunity 2020 Sep;113:102469
Journal of autoimmunity 2020 Sep;113:102469
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y, Jiang Q, Liu X, Lin X, Tang Z, Liu C, Zhou J, Zhao M, Li X, Cheng Z, Li L, Xie Y, Liu Z, Fang W
EBioMedicine 2019 Oct;48:386-404
EBioMedicine 2019 Oct;48:386-404
Lymphocyte-specific protein 1 regulates mechanosensory oscillation of podosomes and actin isoform-based actomyosin symmetry breaking.
Cervero P, Wiesner C, Bouissou A, Poincloux R, Linder S
Nature communications 2018 Feb 6;9(1):515
Nature communications 2018 Feb 6;9(1):515
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The MYH9 antibody from Proteintech is a mouse monoclonal antibody to a fusion protein of human MYH9. This antibody recognizes human, mouse antigen. The MYH9 antibody has been validated for the following applications: ELISA, WB analysis.
